28448233|t|T1 and T2 Mapping in Recognition of Early Cardiac Involvement in Systemic Sarcoidosis
28448233|a|Purpose To determine whether quantitative tissue characterization with T1 and T2 mapping supports recognition of myocardial involvement in patients with systemic sarcoidosis. Materials and Methods Fifty-three consecutive patients with a biopsy-proven extracardiac diagnosis of systemic sarcoidosis (21 men; median age, 45 years; interquartile range, 22 years) and 36 normotensive previously healthy control subjects (14 men; median age, 43 years; interquartile range, 18 years) underwent cardiovascular magnetic resonance imaging, which was performed to assess cardiac function and late gadolinium enhancement, and T1 and T2 mapping. A follow-up substudy was performed in 40 patients (mean follow-up interval, 144 days ± 35 [standard deviation]); of these 40 patients, 18 underwent anti-inflammatory treatment for systemic symptoms. Binary logistic regression and receiver operating characteristic curve analyses were used to assess discrimination between health and disease; Wilcoxon signed rank test was used to assess the effect of treatment. Results When compared with control subjects, patients had higher ventricular volume, higher myocardial native T1 and T2, and lower longitudinal strain and ejection fraction (P < .05 for all). Myocardial native T1 and T2 had higher discriminatory accuracy (area under the receiver operating characteristic curve [AUC]: 0.96 and 0.89, respectively) for separation between control subjects and patients when compared with the standard diagnostic criteria (AUC < 0.67). Native T1 was the independent discriminator between health and disease (specificity, 90%; sensitivity, 96%; accuracy, 94%). There was a significant reduction of native T1 and T2 in the patients who underwent treatment (z score: -3.72 and -2.88; P < .01) but not in the patients who did not (z score, -1.42 and -1.38; P > .15). Conclusion Quantitative myocardial tissue characterization with T1 and T2 mapping may enable noninvasive recognition of cardiac involvement and activity of myocardial inflammation in patients with systemic sarcoidosis. Future studies will be performed to confirm their role in risk stratification and guidance of clinical management. (©) RSNA, 2017 Online supplemental material is available for this article.
28448233	0	2	T1	T081	C2697938
28448233	7	9	T2	T081	C2700066
28448233	10	17	Mapping	T052	C1283195
28448233	21	32	Recognition	T033	C0243095
28448233	36	61	Early Cardiac Involvement	T033	C0243095
28448233	65	85	Systemic Sarcoidosis	UnknownType	C0519072
28448233	115	127	quantitative	T081	C0392762
28448233	128	134	tissue	T024	C0027061
28448233	135	151	characterization	T052	C1880022
28448233	157	159	T1	T081	C2697938
28448233	164	166	T2	T081	C2700066
28448233	167	174	mapping	T052	C1283195
28448233	175	183	supports	T080	C1269765
28448233	184	195	recognition	T033	C0243095
28448233	199	209	myocardial	T024	C0027061
28448233	225	233	patients	T101	C0030705
28448233	239	259	systemic sarcoidosis	UnknownType	C0519072
28448233	295	306	consecutive	T080	C1707491
28448233	307	315	patients	T101	C0030705
28448233	323	336	biopsy-proven	T060	C1304881
28448233	337	359	extracardiac diagnosis	T033	C0011900
28448233	363	383	systemic sarcoidosis	UnknownType	C0519072
28448233	388	391	men	T098	C0025266
28448233	393	399	median	T081	C2348144
28448233	400	403	age	T032	C0001779
28448233	408	413	years	T079	C1510829
28448233	415	434	interquartile range	T081	C1711350
28448233	439	444	years	T079	C1510829
28448233	453	465	normotensive	T033	C2712122
28448233	477	484	healthy	T080	C3898900
28448233	485	501	control subjects	T096	C0009932
28448233	506	509	men	T098	C0025266
28448233	511	517	median	T081	C2348144
28448233	518	521	age	T032	C0001779
28448233	526	531	years	T079	C1510829
28448233	533	552	interquartile range	T081	C1711350
28448233	557	562	years	T079	C1510829
28448233	574	588	cardiovascular	T029	C3887460
28448233	589	615	magnetic resonance imaging	T060	C0024485
28448233	640	646	assess	T058	C0184514
28448233	647	663	cardiac function	T042	C0232164
28448233	668	695	late gadolinium enhancement	T060	C2936236
28448233	701	703	T1	T081	C2697938
28448233	708	710	T2	T081	C2700066
28448233	711	718	mapping	T052	C1283195
28448233	722	731	follow-up	T058	C1522577
28448233	732	740	substudy	T062	C2603343
28448233	745	754	performed	T169	C0884358
28448233	761	769	patients	T101	C0030705
28448233	776	794	follow-up interval	T079	C1272706
28448233	800	804	days	T079	C0439228
28448233	811	829	standard deviation	T081	C0871420
28448233	845	853	patients	T101	C0030705
28448233	868	895	anti-inflammatory treatment	T061	C0087111
28448233	900	917	systemic symptoms	T184	C2039684
28448233	919	945	Binary logistic regression	UnknownType	C0681925
28448233	950	989	receiver operating characteristic curve	T081	C0035787
28448233	990	998	analyses	T062	C0936012
28448233	1012	1018	assess	T058	C0184514
28448233	1019	1033	discrimination	T169	C2945687
28448233	1042	1048	health	T078	C0018684
28448233	1053	1060	disease	T047	C0012634
28448233	1062	1087	Wilcoxon signed rank test	T170	C0871608
28448233	1100	1106	assess	T058	C0184514
28448233	1111	1130	effect of treatment	T033	C1518681
28448233	1159	1175	control subjects	T096	C0009932
28448233	1177	1185	patients	T101	C0030705
28448233	1190	1196	higher	T080	C0205250
28448233	1197	1215	ventricular volume	T081	C1980012
28448233	1217	1223	higher	T080	C0205250
28448233	1224	1234	myocardial	T082	C1522564
28448233	1235	1244	native T1	T081	C2697938
28448233	1249	1251	T2	T081	C2700066
28448233	1257	1262	lower	T080	C0205251
28448233	1263	1282	longitudinal strain	T033	C0243095
28448233	1287	1304	ejection fraction	T033	C2700378
28448233	1324	1334	Myocardial	T082	C1522564
28448233	1335	1344	native T1	T081	C2697938
28448233	1349	1351	T2	T081	C2700066
28448233	1356	1362	higher	T080	C0205250
28448233	1363	1386	discriminatory accuracy	T080	C0598285
28448233	1388	1442	area under the receiver operating characteristic curve	T081	C0376690
28448233	1444	1447	AUC	T081	C0376690
28448233	1502	1518	control subjects	T096	C0009932
28448233	1523	1531	patients	T101	C0030705
28448233	1555	1563	standard	T080	C1442989
28448233	1564	1583	diagnostic criteria	T170	C0679228
28448233	1585	1588	AUC	T081	C0376690
28448233	1598	1607	Native T1	T081	C2697938
28448233	1616	1641	independent discriminator	T080	C0205556
28448233	1650	1656	health	T078	C0018684
28448233	1661	1668	disease	T047	C0012634
28448233	1670	1681	specificity	T081	C1511884
28448233	1688	1699	sensitivity	T081	C1511883
28448233	1706	1714	accuracy	T080	C0598285
28448233	1734	1755	significant reduction	T061	C0441610
28448233	1759	1768	native T1	T081	C2697938
28448233	1773	1775	T2	T081	C2700066
28448233	1783	1791	patients	T101	C0030705
28448233	1806	1815	treatment	T061	C0087111
28448233	1817	1824	z score	T081	C0871421
28448233	1856	1859	not	T033	C0205160
28448233	1867	1875	patients	T101	C0030705
28448233	1884	1887	not	T033	C0205160
28448233	1889	1896	z score	T081	C0871421
28448233	1936	1948	Quantitative	T081	C0392762
28448233	1949	1966	myocardial tissue	T024	C0027061
28448233	1967	1983	characterization	T052	C1880022
28448233	1989	1991	T1	T081	C2697938
28448233	1996	1998	T2	T081	C2700066
28448233	1999	2006	mapping	T052	C1283195
28448233	2018	2041	noninvasive recognition	T058	C0814177
28448233	2045	2064	cardiac involvement	T033	C0243095
28448233	2069	2077	activity	T052	C0441655
28448233	2081	2104	myocardial inflammation	T047	C0027059
28448233	2108	2116	patients	T101	C0030705
28448233	2122	2142	systemic sarcoidosis	UnknownType	C0519072
28448233	2151	2158	studies	T062	C2603343
28448233	2167	2176	performed	T169	C0884358
28448233	2202	2206	risk	T078	C0035647
28448233	2207	2221	stratification	T062	C1514983
28448233	2226	2234	guidance	T058	C0150600
28448233	2238	2257	clinical management	T058	C1516615